Longer-term assessments of outcomes needed, researchers say
MONDAY, March 27, 2017 (HealthDay News) — Several classes of drugs reduce neuropathy-related pain better than placebo, according to a review published online March 24 in Neurology.
Julie M. Waldfogel, Pharm.D., from the Johns Hopkins Hospital in Baltimore, and colleagues conducted a systematic literature review to evaluate the effect of pharmacologic treatments of diabetic peripheral neuropathy (DPN) on pain and quality of life.
The researchers identified an additional 24 published studies and 25 unpublished studies, since the last completed systematic review of 57 eligible studies. Compared to placebo, the serotonin-norepinephrine reuptake inhibitors duloxetine and venlafaxine (moderate strength of evidence [SOE]), the anticonvulsants pregabalin and oxcarbazepine (low SOE), the drug classes tricyclic antidepressants (low SOE) and atypical opioids (low SOE), and botulinum toxin (low SOE) were more effective for reducing neuropathy-related pain. Incomplete reporting prevented conclusions about quality of life. All evaluated studies were short-term (less than six months), and for all effective drugs, adverse effects caused >9 percent dropout rates.
“Future studies should evaluate longer-term outcomes, use methods, and measures recommended by pain organizations, and assess patients’ quality of life,” the authors write.
Abstract
Full Text (subscription or payment may be required)
Copyright © 2017 HealthDay. All rights reserved.
